Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodinated activated charcoal (IAC) is a modified form of activated charcoal in which iodine is incorporated into the structure. Activated charcoal itself is an amorphous carbon material with a highly porous surface, used primarily as a gastric decontaminant to treat poisonings by adsorbing drugs and toxins in the gastrointestinal tract[2][3][4]. Iodinated activated charcoal has been studied for additional therapeutic effects; notably, an oral formulation was shown in a double-blind randomized controlled trial to significantly improve lung function in patients with moderate chronic obstructive pulmonary disease (COPD), as measured by FEV1 improvement compared to placebo[5]. The mechanism of action for this effect remains unclear but appears distinct from standard COPD therapies. Some patients experienced transient abnormal thyroid hormone levels during treatment, likely related to iodine content[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iodinated activated charcoal.